Advertisement
Product › Details
C. difficile vaccine (Sanofi Pasteur)
Next higher product group | vaccine_o | |
Status | 2017-12-01 development p3 end–negat | |
Organisation | Sanofi Pasteur (Group) | |
Group | Sanofi (Group) [since May 2011] | |
Sanofi S.A.. (12/1/17). "Press Release: Sanofi Ends Development of Clostridium Difficile Vaccine". Paris.
Following a planned interim analysis, the Independent Data Monitoring Committee (IDMC) for the phase III Cdiffense clinical trial program concluded that the probability that the study will meet its primary objective is low. Based on this, Sanofi has therefore decided to discontinue clinical development of its experimental Clostridium difficile vaccine, to focus on six key vaccine projects currently in development.
Cdiffense is a trial designed to test the efficacy and safety of a candidate toxoid vaccine in a subpopulation at risk of Clostridium difficile infection.
Sanofi Pasteur, the vaccines business of Sanofi responsible for the program, is informing all investigators, regulatory authorities and trial ethics committees. In addition, investigators are notifying study volunteers of the decision to stop the program. Data from all vaccinated volunteers in this trial will continue to be analyzed for more information and shared with the scientific community.
About Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life
Record changed: 2023-07-10 |
Advertisement
More documents for vaccine_o
- [1] Valneva S.E.. (11/10/23). "Press Release: Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, Ixchiq". Saint Herblain....
- [2] Valneva S.E.. (11/9/23). "Press Release: Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates". Saint Herblain....
- [3] Valneva S.E.. (11/7/23). "Press Release: Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference". Saint Herblain....
- [4] Valneva S.E.. (10/25/23). "Press Release: Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment". Saint Herblain....
- [5] Valneva S.E.. (9/25/23). "Press Release: Valneva Announces New Ixiaro Supply Contract with the U.S. Government Worth a Minimum of $32 Million". Saint Herblain....
- [6] Valneva S.E.. (11/17/22). "Press Release: Valneva Appoints Dipal Patel as Chief Commercial Officer". Saint-Herblain....
- [7] Immunethep S.A.. (10/18/22). "Press Release: Immunethep Receives Funding from the European Innovation Council for Clinical Trials". Cantanhede....
- [8] Valneva S.E.. (8/18/22). "Press Release: Valneva Provides Update on Ixiaro Supply Contract with U.S. Department of Defense". Saint-Herblain....
- [9] GSK plc. (5/31/22). "Press Release: GSK to Acquire Clinical-stage Biopharmaceutical Company Affinivax, Inc.". London....
- [10] Valneva S.E.. (9/3/21). "Press Release: Valneva – U.S. DoD Exercises First Year Option on Ixiaro Supply Contract". Saint-Herblain....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top